ImmuPharma (LON:IMM) Stock Price Up 13.9% – Still a Buy?

ImmuPharma plc (LON:IMM)’s share price shot up 13.9% during mid-day trading on Wednesday . The stock traded as high as GBX 15.15 ($0.20) and last traded at GBX 12.67 ($0.17). 50,412,297 shares traded hands during trading, an increase of 548% from the average session volume of 7,783,485 shares. The stock had previously closed at GBX 11.13 ($0.15).

ImmuPharma Price Performance

The company has a market cap of £63.14 million, a price-to-earnings ratio of -1,419.55 and a beta of 1.53. The business has a 50 day simple moving average of GBX 2.55 and a 200 day simple moving average of GBX 2.76.

ImmuPharma (LON:IMM) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.